Hsueh Y.-M.Su C.-T.Shiue H.-S.Chen W.-J.YEONG-SHIAU PULin Y.-C.Tsai C.-S.CHAO-YUAN HUANG2021-02-022021-02-0220170278-6915https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021454128&doi=10.1016%2fj.fct.2017.06.031&partnerID=40&md5=190bcfe2abe579d2ece621640d4bd330https://scholars.lib.ntu.edu.tw/handle/123456789/544325This study investigated whether plasma selenium levels modified the risk for prostate cancer (PC) related to arsenic exposure. We conducted a case-control study that included 318 PC patients and 318 age-matched, healthy control subjects. Urinary arsenic profiles were examined using HPLC-HG-AAS and plasma selenium levels were measured by ICP-MS. We found that plasma selenium levels displayed a significant dose-dependent inverse association with PC. The odds ratio (OR) and 95% confidence interval (CI) for PC was 0.07 (0.04–0.13) among participants with a plasma selenium level >28.06 μg/dL vs. ?19.13 μg/dL. A multivariate analysis showed that participants with a urinary total arsenic concentration >29.28 μg/L had a significantly higher OR (1.75, 1.06–2.89) for PC than participants with ?29.89 μg/L. The combined presence of a low plasma selenium level and a high urinary total arsenic concentration exponentially increased the OR for PC, and additively interacted with PSA at levels ?20 ng/mL. This is the first epidemiological study to examine the combined effects of plasma selenium and urinary total arsenic levels on the OR for PC. Our data suggest a low plasma selenium level coupled with a high urinary total arsenic concentration creates a significant risk for aggressive PC. ? 2017 Elsevier Ltd[SDGs]SDG3arsenic; selenium; arsenic; selenium; aged; arsenic urine level; Article; cancer inhibition; cancer risk; case control study; controlled study; high performance liquid chromatography; human; informed consent; limit of detection; limit of quantitation; major clinical study; male; mass spectrometry; prostate cancer; selenium blood level; urine level; blood; Prostatic Neoplasms; urine; Aged; Arsenic; Case-Control Studies; Humans; Male; Prostatic Neoplasms; Seleniumjournal article10.1016/j.fct.2017.06.031286341112-s2.0-85021454128